Marinus Pharmaceuticals (MRNS) Releases Quarterly Earnings Results

Marinus Pharmaceuticals (NASDAQ:MRNS) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.06), MarketWatch Earnings reports.

Shares of NASDAQ:MRNS traded down $0.09 during trading on Tuesday, hitting $4.78. The company’s stock had a trading volume of 10,881 shares, compared to its average volume of 814,209. The company has a market cap of $203.84 million, a price-to-earnings ratio of -5.85 and a beta of 2.53. Marinus Pharmaceuticals has a fifty-two week low of $3.31 and a fifty-two week high of $10.54.

Several equities analysts have commented on the stock. ValuEngine downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. BidaskClub downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Mizuho restated a “buy” rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 25th. Finally, Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $19.67.



An institutional investor recently raised its position in Marinus Pharmaceuticals stock. Bank of New York Mellon Corp lifted its position in shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 190.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 106,560 shares of the biopharmaceutical company’s stock after purchasing an additional 69,863 shares during the period. Bank of New York Mellon Corp owned about 0.26% of Marinus Pharmaceuticals worth $754,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 63.68% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Further Reading: Why is the conference call important?

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply